10:09 AM EDT, 08/22/2024 (MT Newswires) -- Sutro Biopharma ( STRO ) said Thursday it has initiated a global phase 2 study evaluating luveltamab tazevibulin, or luvelta, in patients with non-small cell lung cancer whose tumor expresses Folate Receptor-alpha.

The study, which is now open for enrollment, aims to evaluate the safety and efficacy of luvelta in adults with previously treated advanced or metastatic NSCLC with FRalpha expression of at least 25% tumor proportion score, the company said.

Initial data from this study is expected in the first half of 2025, Sutro Biopharma ( STRO ) added.

Price: 4.59, Change: +0.03, Percent Change: +0.66